Tag Archives: Mara Goldstein

Cantor Fitzgerald Believes Array Biopharma (NASDAQ: ARRY) Still Has Room to Grow

Cantor Fitzgerald analyst Mara Goldstein maintained a Buy rating on Array Biopharma (NASDAQ: ARRY) today and set a price target of $26. The company’s shares closed on Friday at $19.37, close to its 52-week high of $20.21. Goldstein commented: “.

Cantor Fitzgerald Sticks to Its Hold Rating for Cytokinetics Inc

Cantor Fitzgerald analyst Mara Goldstein maintained a Hold rating on Cytokinetics Inc (NASDAQ: CYTK) yesterday and set a price target of $10. The company’s shares closed on Friday at $9.90. Goldstein noted: “Reldesemtiv and omecamtiv mecarbil, CYTK’s lead programs, have

Flex Pharma Gets a Hold Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Mara Goldstein maintained a Hold rating on Flex Pharma (NASDAQ: FLKS) today and set a price target of $6. The company’s shares closed yesterday at $4.18. Goldstein commented: “Our rating on FLKS is Neutral. Our price target

Progenics Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Mara Goldstein maintained a Buy rating on Progenics (NASDAQ: PGNX) yesterday and set a price target of $15. The company’s shares closed on Friday at $7.23. Goldstein said: “. We maintain an Overweight rating and 12-month PT

Radius Health Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Mara Goldstein maintained a Buy rating on Radius Health (NASDAQ: RDUS) yesterday and set a price target of $58. The company’s shares closed yesterday at $31.77. Goldstein observed: “TYMLOS Growing the Market. RDUS reported 1Q18 sales of

Cantor Fitzgerald Maintains a Hold Rating on NewLink

Cantor Fitzgerald analyst Mara Goldstein maintained a Hold rating on NewLink (NASDAQ: NLNK) yesterday and set a price target of $7. The company’s shares closed yesterday at $4.87, close to its 52-week low of $3.75. Goldstein noted: “Retooling the Program.